Gilead (GILD) Sovaldi Prescriptions Tracking Down 16% Q/Q - RBC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Gilead (GILD) Sovaldi Prescriptions Tracking Down 16% Q/Q - RBC

Gilead Sciences (GILD) Receives Marketing Approval for Zydelig in Europe

September 19, 2014 6:24 AM EDT

Gilead Sciences (Nasdaq: GILD) announced that the European Commission has granted marketing authorization for Zydelig (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. For the treatment of FL, Zydelig has been approved as a monotherapy in... More